Johnson & Johnson (NYSE:JNJ) Price Target Raised to $225.00 at Sanford C. Bernstein

Johnson & Johnson (NYSE:JNJ) had its price objective upped by analysts at Sanford C. Bernstein from $208.00 to $225.00 in a research report issued on Friday,MarketScreener reports. The firm currently has a “market perform” rating on the stock. Sanford C. Bernstein’s price objective indicates a potential upside of 2.26% from the company’s current price.

A number of other analysts also recently issued reports on JNJ. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Royal Bank Of Canada set a $240.00 price objective on Johnson & Johnson in a research note on Wednesday, December 17th. Morgan Stanley lifted their price target on Johnson & Johnson from $197.00 to $200.00 and gave the stock an “equal weight” rating in a report on Thursday. Citigroup increased their price objective on shares of Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a research note on Monday, October 20th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $224.82.

Johnson & Johnson Stock Up 0.7%

NYSE:JNJ traded up $1.55 during trading hours on Friday, reaching $220.04. The company’s stock had a trading volume of 570,586 shares, compared to its average volume of 9,340,856. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market cap of $530.13 billion, a price-to-earnings ratio of 19.92, a price-to-earnings-growth ratio of 2.24 and a beta of 0.34. Johnson & Johnson has a one year low of $141.50 and a one year high of $222.17. The business’s 50-day moving average is $207.86 and its 200-day moving average is $188.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company had revenue of $24.56 billion during the quarter, compared to analysts’ expectations of $24.14 billion. During the same quarter in the previous year, the firm earned $2.04 earnings per share. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Institutional Trading of Johnson & Johnson

A number of hedge funds have recently added to or reduced their stakes in the stock. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at approximately $26,000. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson during the 2nd quarter worth about $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $28,000. Semmax Financial Advisors Inc. lifted its stake in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the period. Finally, GFG Capital LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $35,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 beat and raised 2026 outlook — JNJ topped earnings and revenue estimates, reported stronger organic growth and issued 2026 guidance that management says should exceed Street expectations, supporting bullish sentiment. JNJ Tops Q4 Earnings
• Positive Sentiment: Analyst upgrades and higher targets — Several firms raised price targets (notably Scotiabank to $265) and the consensus broker view is skewed toward buy/moderate buy, which supports further upside. Scotiabank Raises JNJ Target
• Positive Sentiment: Dividend credibility and cash returns — J&J’s Dividend King status (63+ years of raises), healthy payout ratio and buyback capacity keep income investors supportive. Dividend King Analysis
• Neutral Sentiment: Technical setup — Analysts/market outlets note a trend‑following buy signal after the post‑earnings pullback, which can attract momentum flows but is dependent on macro/sector breadth. MarketBeat Technical Note
• Neutral Sentiment: Media and TV endorsements — Positive commentary from high‑profile commentators (e.g., Jim Cramer) may underpin short‑term interest but has limited fundamental impact. Jim Cramer on JNJ
• Negative Sentiment: Talc litigation advances — A court decision cleared the way for plaintiffs’ expert testimony in the talc MDL, a legal overhang that can resume volatility and possible liability risk. Talc Litigation Update
• Negative Sentiment: Stelara biosimilar pressure — Loss of Stelara patent protection and accelerating biosimilar competition dented prior sales and remain a medium‑term headwind for revenue mix. Stelara Biosimilar Headwind
• Negative Sentiment: Drug‑pricing deal cost — Management flagged “hundreds of millions” of costs tied to a recent drug‑pricing agreement, which modestly offsets EPS upside in 2026. Guidance & Pricing Headwind

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.